Algert Global’s Cue Biopharma CUE Stock Holding History

Algert Global’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-441	Closed	-$48K	–	1134
2023 Q2	$48K	Buy	+441	New	+$51.8K	﹤0.01%	1059

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Algert Global's CUE Position: Q3 2023 in Review

Algert Global sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 441 shares — an estimated $48K sold.

Algert Global first reported a position in CUE in Q2 2023 and held it in 1 quarter. The position peaked at $48K in Q2 2023. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

Algert Global reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
Algert Global sold 441 Cue Biopharma shares in Q3 2023, an estimated $48K.
Algert Global first reported a position in Cue Biopharma in Q2 2023 and held it in 1 quarter.
Algert Global's Cue Biopharma position peaked at $48K in Q2 2023.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on Algert Global's 13F filing for Q3 2023, filed 13 Nov 2023.